Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has issued an update.
ResMed reported its monthly CHESS Depositary Interests statement for March 2026, showing 564,629,900 CDIs on issue over quoted securities at month-end, down from 574,157,700 in February, primarily due to net transfers between CDIs on the ASX and common stock traded on the NYSE. Over the same period, the number of underlying securities over which CDIs have not been issued increased, reflecting transfers between ASX CDIs and NYSE-listed shares, issuance of new stock for employee equity plans, and ongoing share repurchases on the NYSE, indicating active capital management and cross-market movement in its share base.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$36.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical device company that develops and manufactures equipment and software for the diagnosis, treatment and management of sleep-disordered breathing and other chronic respiratory conditions. The company is listed on the NYSE and its CHESS Depositary Interests (CDIs) trade on the ASX on a 10-to-1 ratio to its common stock.
Average Trading Volume: 1,201,111
Technical Sentiment Signal: Hold
Current Market Cap: A$47.33B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.